MicroRNAs in Soft Tissue Sarcomas: Overview of the Accumulating Evidence and Importance as Novel Biomarkers

Table 2

Studies on circulating miRNAs in the serum of patients with soft tissue sarcomas.

Histology	Promising circulating miRNAs	Study design	Samples	Sample size	Methods	Number of miRNAs examined	Normalization	References
Rhabdomyosarcoma	miR-206	RMS; versus non-RMS; versus healthy; individual	Serum	8 RMS patients; versus 23 non-RMS patients; versus 17 healthy controls	qRT-PCR	4 miRNAs	miR-16	[106]
Malignant peripheral; nerve sheath tumor	miR-24, 801, and 214	Sporadic MPNST; versus NF1 MPNST; versus NF1	Serum	(Screening); 10 sporadic MPNSTs; versus 10 NF1 MPNSTs; versus 10 NF1	Solexa sequencing, qRT-PCR	Genome-wide profiling	cel-miR-39	[108]
				(Validation); 83 sporadic MPNSTs; versus 61 NF1 MPNSTs; versus 90 NF1

RMS: rhabdomyosarcoma; MPNST: malignant peripheral nerve sheath tumor; NF1: neurofibromatosis type 1.